News|Articles|September 9, 2025

EADV Congress 2025: Late-Breaking Trials Preview

Fact checked by: Tim Smith

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Among dermatologists and other clinicians in the skin health space, the European Academy of Dermatology and Venereology (EADV) Congress is more than just a yearly meeting—it is a venue at which new data can shift existing standards of care and redefine treatment approaches. The late-breaking abstract sessions each year during the EADV Congress bring forward findings that can help to not only inform decision-making but also spark debate, collaboration, and momentum across dermatology.

Related to this article

October 2nd, 2026

7 Dermatology Headlines You Missed in September 2026

From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.

October 5th, 2026

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

October 5th, 2026

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

October 3rd, 2026

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

October 3rd, 2026

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

October 3rd, 2026

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

October 2nd, 2026

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

October 2nd, 2026

ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years

Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.